A. Michael Lincoff
Department of Cardiovascular Medicine
Cleveland Clinic
9500 Euclid Avenue/J2-3
Cleveland
Name/email consistency: high
- Safety profile and bleeding risk of ticagrelor compared with clopidogrel. May, C.H., Lincoff, A.M. Expert. Opin. Drug. Saf (2012)
- Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Lincoff, A.M., Steinhubl, S.R., Manoukian, S.V., Chew, D., Pollack, C.V., Feit, F., Ware, J.H., Bertrand, M.E., Ohman, E.M., Desmet, W., Cox, D.A., Mehran, R., Stone, G.W. JACC. Cardiovasc. Interv (2008)
- Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E. JAMA (2007)
- How do unfractionated and low-molecular-weight heparin compare after ST-segment elevation MI?. Lincoff, A.M. Nature Clinical Practice. Cardiovascular Medicine (2006)
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Lincoff, A.M., Bittl, J.A., Kleiman, N.S., Sarembock, I.J., Jackman, J.D., Mehta, S., Tannenbaum, M.A., Niederman, A.L., Bachinsky, W.B., Tift-Mann, J., Parker, H.G., Kereiakes, D.J., Harrington, R.A., Feit, F., Maierson, E.S., Chew, D.P., Topol, E.J. Am. J. Cardiol. (2004)
- Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. Lincoff, A.M., Kleiman, N.S., Kereiakes, D.J., Feit, F., Bittl, J.A., Jackman, J.D., Sarembock, I.J., Cohen, D.J., Spriggs, D., Ebrahimi, R., Keren, G., Carr, J., Cohen, E.A., Betriu, A., Desmet, W., Rutsch, W., Wilcox, R.G., de Feyter, P.J., Vahanian, A., Topol, E.J. JAMA (2004)
- Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. Lincoff, A.M., Bittl, J.A., Harrington, R.A., Feit, F., Kleiman, N.S., Jackman, J.D., Sarembock, I.J., Cohen, D.J., Spriggs, D., Ebrahimi, R., Keren, G., Carr, J., Cohen, E.A., Betriu, A., Desmet, W., Kereiakes, D.J., Rutsch, W., Wilcox, R.G., de Feyter, P.J., Vahanian, A., Topol, E.J. JAMA (2003)
- Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Lincoff, A.M. Circulation (2003)
- Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Lincoff, A.M., Kleiman, N.S., Kottke-Marchant, K., Maierson, E.S., Maresh, K., Wolski, K.E., Topol, E.J. Am. Heart J. (2002)
- Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. Lincoff, A.M., Califf, R.M., Van de Werf, F., Willerson, J.T., White, H.D., Armstrong, P.W., Guetta, V., Gibler, W.B., Hochman, J.S., Bode, C., Vahanian, A., Steg, P.G., Ardissino, D., Savonitto, S., Bar, F., Sadowski, Z., Betriu, A., Booth, J.E., Wolski, K., Waller, M., Topol, E.J. JAMA (2002)
- Update on Pharmacology for Restenosis. Chan, A.W., Chew, D.P., Lincoff, A.M. Curr. Interv. Cardiol. Rep (2001)
- Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Lincoff, A.M., Kereiakes, D.J., Mascelli, M.A., Deckelbaum, L.I., Barnathan, E.S., Patel, K.K., Frederick, B., Nakada, M.T., Topol, E.J. Circulation (2001)
- Anticoagulant and antiplatelet drugs. Lincoff, A.M. Catheter. Cardiovasc. Interv (2001)
